Aoc 1044
Genetic Diseases
Avidity Biosciences, Inc.nucleic_acidPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Genetic Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Intergroupe Francophone du Myelome | Phase 3 | BB |
Zeleciment Rostudirsen Dyne Therapeutics | Phase 3 | B |
DEXAMETHASONE Quince Therapeutics S.p.A. | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
FULVESTRANT Borstkanker Onderzoek Groep | Phase 2 | CCC |
View all 16 →
Same molecule, other indications
Aoc 1044 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →